A Prospective, Single-arm Study Evaluating the Endothelialization Effect and Timeline of AnchorMan® Left Atrial Appendage Occluder in Non-valvular Atrial Fibrillation Patients at High Risk of Stroke (AnchorMan-NVAF)

This study aims to evaluate the endotheliation efficacy of the AnchorMane® Left Atrial Appendage Occluder in non-valvular atrial fibrillation patients at high stroke risk. It investigates the rate of complete endotheliation of the occluder at 6 months post-procedure using routine cardiac CTA, providing additional data for clinical application and further product development.

Study Size and Duration: This study plans to enrol1 306 patients. All participants will undergo follow up immediately after occluder implantation, prior to discharge or within 7 days post-procedure, at 1 month post-procedure, at 3 months post-procedure,and at 6 months post-procedure. The total study duration is projected to be 3 year.

The expected duration of participation for each participant is approximately 6 months.

Study Overview

• Status: Not yet recruiting
• Conditions: Non-valvular Atrial Fibrillation (NVAF); High Risk of Stroke
• Intervention / Treatment: Procedure: Intra-operative application of LAAC

Detailed Description

Endothelialization within the left atrial appendage represents a core biological process following transcatheter left atrial appendage closure (LAAC). Advances in this field directly influence the optimization of postoperative anticoagulation strategies and the control of device related thrombosis (DRT) risks.

This multicenter, prospective, single-arm study primarily investigates the endotheliation efficacy of the AnchorMane® Left Atrial Appendage Occlusion Device using cardiac CTA following left atrial appendage occlusion. It plans to enroll 306 non-valvular atrial fibrillation patients undergoing left atrial appendage occlusion device for followup observation of the time course of device surface with the.endotheliation.

The device used in this study is the approved AnchorMane® Left Atrial Appendage Occlusion System, which is routinely employed in clinical practice.

What is required of me if I participate in the study?

If you decide to participate in this study, you will be enrolled after signing the informed consent form with full understanding. Participation in this trial requires your cooperation with the study physician to complete the following examinations or procedures :

• Baseline Visit (within 7 days pre-op): Collection of routine medical history, demographic data, physical examination,vital signs, modified Rankin Scale (mRS) score (if applicable), CHA2DS2,-VASc score.HAS-BLED score, NYHA functional class, electrocardiogram (EcG), laboratory tests(complete blood count, urinalysis, blood chemistry, coagulation profile, blood/urine pregnancy testif indicated, serum inflammatory markers),transesophageal echocardiography(TEE), and transthoracic echocardiography (TTE).
• Baseline Visit (Intra-operative): Vital signs, serum inflammatory markers, left atrial angiography, surgical records, medication records. Collect and document endpoint events and other adverse events.
• Discharge/Post-op 7-day Visit: Collect vital signs, modified Rankin Scale (mRS)score (if applicable), NYHA functional class, transthoracic echocardiogram (TTE), and laboratory test results (complete blood count, urinalysis, blood biochemistry, coagulation function, serum inflammatory markers)Complete medication records and collect/record for routine clinical care.information on endpoint events and other adverse events.
• 1-month Follow-up (±7 days): Collect results from routine diagnostic procedures including cardiac ultrasound (if applicable), cardiac CTA (if applicable), and laboratory tests.Complete documentation of medication history, endpoint events, and other adverse event information.
• 3-month Follow-up (±15 days): Complete and collect your routine clinical vital signs, cardiac ultrasound (if applicable), cardiac CTA, and serum inflammatory marker test results.Complete medication records, endpoint event documentation, and other adverse event records.
• 6-month Follow-up (±30 days): Complete and collect results of routine clinical examinations including vital signs, cardiac ultrasound, cardiac CTA, and serum inflammatory markers. Complete medication records, endpoint event documentation, and other adverse event records.
• Note: Laboratory tests included in the study comprise: Complete blood count : Collect hemoglobin, red blood cell, white blood cell, and platelet counts; Urinalysis: Collect urine red blood cells, urine white blood cells, urine protein, and urine glucose levels. Blood Biochemistry: Preoperative testing for total cholesterol, triglycerides,LDL cholesterol, HDl cholesterol, Creatinine, BUN, fasting blood glucose, albumin, ALT,AST; Pre-discharge Creatinine, alanine aminotransferase (ALT)，aspartatetests: aminotransferase (AsT). Coagulation function tests: Prothrombin time (PT), Prothrombintime international normalized ratio (INR), Activated partial thromboplastin time (APTT),Thrombin time (TT). Approximately 3 ml of blood will be drawn for each blood test, and approximately 3 ml of urine will be collected for each urine test. Your blood and urine samples will be used solely for routine hospital analysis and will not be sent externally.Remaining samples will be destroyed according to standard hospital protocols. During the study, we will need to collect your imaging data. This data will undergo de-identification and will be used exclusively for this research.

• Study Type: Interventional
• Enrollment (Estimated): 306
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: wenzhi pan; Phone Number: 0755-1234567; Email: peden@sina.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Age ≥ 18 years with non-valvular atrial fibrillation (NVAF).

2. High stroke risk: CHA2DS2-VASc score ≥ 2 (Male) or ≥ 3 (Female) AND meeting any of the following:

   1. Documented history of bleeding (> 6 months ago) or bleeding tendency (e.g., gingival, nasal, GI, urinary tract, cerebral hemorrhage).
   2. Intolerance or unwillingness to undergo long-term anticoagulation therapy.
   3. Recurrent stroke or embolic events despite standardized anticoagulation.
   4. Predicted high bleeding risk (HAS-BLED score ≥ 3).
   5. Status post-Left Atrial Appendage Electrical Isolation (LAAEI).
3. Subject or legal representative understands the study purpose, is willing to cooperate with surgery and follow-up, and has signed the written Informed Consent Form (ICF).

Exclusion Criteria:

1. Rheumatic heart disease, moderate-to-severe mitral stenosis/regurgitation, severe aortic valve disease, or severe LVOT obstruction (gradient > 40 mmHg).
2. Left ventricular ejection fraction (LVEF) < 30%.
3. Complex LAA anatomy unsuitable for LAAO implantation.
4. Pericardial effusion > 10mm.
5. Planned ablation or cardioversion post-procedure.
6. Intracardiac thrombus (including left/right atrium).
7. Myocardial infarction within the last 3 months.
8. History of ASD repair or PFO occluder implantation.
9. History of heart valve replacement (mechanical valve).
10. Heart transplant recipient.
11. New-onset ischemic stroke or TIA within the last 30 days.
12. Severe heart failure (NYHA Class IV).
13. Severe renal impairment: eGFR < 45 ml/min/1.73m² or on dialysis.
14. Hypersensitivity or contraindication to aspirin, clopidogrel, heparin, contrast media, or nitinol.
15. Pregnant or lactating women, or those planning pregnancy within one year.
16. Life expectancy < 12 months.
17. Unable to complete 2 months of anticoagulation or 6 months of DAPT for any reason.
18. Investigator's judgment of poor compliance or inability to complete the study requirements.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Treatment Group; AnchorMan® Left Atrial Appendage Occluder System Treatment	Procedure: Intra-operative application of LAAC; Undergoing left atrial appendage occlusion device for followup observation of the time course of device surface with the.endotheliation.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Complete endothelialization rate of the LAA occluder	The proportion of subjects whose cardiac CTA shows complete endothelialization of the LAAO at 6 months post-occlusion. Complete endothelialization is defined as LAA density < 100 HU or < 25% of left atrial (LA) density under cardiac CTA examination.	6 months post-procedure.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Device success rate	The proportion of subjects who correctly deployed and implanted the device in the appropriate location	immediate post-procedure
Clinical success rate	The proportion of patients who do not experience ischemic stroke, hemorrhagic stroke, systemic embolism, cardiovascular death, or death of unknown cause after occlusion.	6 months post-operation
Procedural success rate	Successful left atrial appendage occlusion with no device-related complications at discharge or within 7 days post-operation (whichever comes first).	7 days post-operation or at discharge
Incidence of stroke and transient ischemic attack (TIA)	Stroke is defined as all strokes in the Valve Research Consortium (VARC-3), specifically including ischemic stroke, hemorrhagic stroke, and undetermined stroke.	3 months post-operation, 6 months post-operation
Incidence of systemic embolism	Embolism other than stroke, such as myocardial infarction, pulmonary embolism, renal infarction, splenic infarction, limb ischemia, mesenteric ischemia, etc.	3 months post-operation, 6 months post-operation
Serious bleeding events	Serious bleeding refers to bleeding events of types 3-5 as defined in the Bleeding Research Consortium (BARC)	before discharge or 7 days post-operation, 3 months post-operation, 6 months post-operation
All-cause mortality	Refer to the definition in VARC-3, which refers to death from any cause, including cardiovascular and non-cardiovascular death.	before discharge or 7 days post-operation, 3 months post-operation, 6 months post-operation
Incidence of Device-Related Complications	Device-related complications include device embolism, device corrosion, clinically significant device-to-surrounding structure interference, device thrombosis, device breakage, device infection/endocarditis/pericarditis, device perforation/tear, device allergy-induced cardiac tamponade, pericardial effusion requiring intervention, occluder embolism, and cardiac perforation.	6 Months Post-Op
Occluder Performance	Cardiac CTA or transesophageal (or chest wall) echocardiography was used to evaluate the device, including displacement, dislodgement, mitral regurgitation, residual shunt, and device-related thrombosis. The incidence of these events was calculated.	6 Months Post-Op
Left atrial appendage occluder complete endothelialization rate	The proportion of subjects whose cardiac CTA shows complete endothelialization of the LAAO at 3 months post-occlusion. Complete endothelialization is defined as LAA density < 100 HU or < 25% of left atrial (LA) density under cardiac CTA examination.	3 months post-operation
Device-related thrombosis (DRT) incidence	assessed using cardiac CTA. DRT appears as a low-density filling defect on the left atrial side of the device surface. A thicker (>3 mm) and more prominent low-density defect is considered a typical manifestation of DRT.	3 months post-operation, 6 months post-operation
Residual Leak (PDL) Incidence	Cardiac CTA was used for assessment. A residual left atrial appendage density ≥100 HU or ≥25% of the left atrial density indicated the presence of a PDL. If TEE was used for assessment, residual shunts were classified based on color jet width as: minimal (1 mm), mild (1-3 mm), or relatively significant (3 mm). Complete closure was defined as no residual shunt greater than 5 mm on TEE examination.	before discharge or 7 days post-operation, 3 months post-operation, 6 months post-operation
Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)	MACCE includes perioperative complications and long-term follow-up complications. Specifically: Perioperative complications: death, cardiac tamponade, device embolism, stroke, severe bleeding, and vascular access complications;; Long-term follow-up complications: ischemic stroke, hemorrhagic stroke, thromboembolism, device-related thrombosis, severe bleeding, and death.	3 months post-operation, 6 months post-operation

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Serum inflammatory markers	Serum inflammatory markers[18] mainly include high-sensitivity C-reactive protein (Hs-CRP), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), platelet-derived growth factor (PDGF), transforming growth factor-β (TGF-β), vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), matrix metalloproteinase-9 (MMP-9), and von Willebrand factor (vWF).	preoperative, 24 hours postoperative, 1 week postoperative/before discharge (whichever comes first), 1 month postoperative, 3 months postoperative, 6 months postoperative

Collaborators and Investigators

• Sponsor: Shanghai Zhongshan Hospital
• Collaborators: Changhai Hospital; Ruijin Hospital; Xinhua Hospital, Shanghai Jiao Tong University School of Medicine; Zhoupu Hospital, Pudong New Area, Shanghai, China

Study record dates

Study Major Dates

• Study Start (Estimated): February 8, 2026
• Primary Completion (Estimated): June 12, 2027
• Study Completion (Estimated): December 31, 2027

Study Registration Dates

• First Submitted: January 19, 2026
• First Submitted That Met QC Criteria: February 2, 2026
• First Posted (Actual): February 9, 2026

Study Record Updates

• Last Update Posted (Actual): February 9, 2026
• Last Update Submitted That Met QC Criteria: February 2, 2026
• Last Verified: February 1, 2026

More Information

Terms related to this study

• Keywords: Non-valvular atrial fibrillation (NVAF); high risk of stroke.; Left Atrial Appendage Occluder System
• Other Study ID Numbers: AM-PM-02; 25SF1902201 (Other Grant/Funding Number: Shanghai Science and Technology Commission)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No